Evelyn P Murphy1, Niall P McGoldrick2, Mark Curtin3, Stephen R Kearns4. 1. Department of Trauma and Orthopaedics, Galway University Hospital, Saolta Hospital Group, Ireland. Electronic address: evelynpmurphy@rcsi.ie. 2. Department of Trauma and Orthopaedics, Galway University Hospital, Saolta Hospital Group, Ireland. Electronic address: niallmcgoldrick@rcsi.ie. 3. Department of Trauma and Orthopaedics, Galway University Hospital, Saolta Hospital Group, Ireland. Electronic address: markcurtin@rcsi.ie. 4. Department of Trauma and Orthopaedics, Galway University Hospital, Saolta Hospital Group, Ireland. Electronic address: Stephen.kearns@hse.ie.
Abstract
BACKGROUND: The term osteochondral lesion (OCL) refers to a defect involving the chondral surface and or subchondral bone. These lesions are associated with ankle injuries with bony and soft tissue and cause pain, decreased range of motion, swelling and impact adversely on quality of life. To date the standard treatment has been isolated microfracture (BMS). The aim of this study was to compare the outcomes of BMS alone to BMS augmented with bone marrow aspirate concentrate (BMAC) in the treatment of ankle OCLs. METHODS: This study was a prospective cohort study carried out from 2010-2015 in a single surgeon's practice. Patients from 2010-2012 were treated with microfracture alone while patients from 2013-2015 were treated with micro fracture augmented with bone marrow aspirate concentrate and fibrin glue. Self-reported patient outcome measures were measured. Complications, revision rates, and visual analogue pain scores were compared. RESULTS: 101 patients were included in the study. 52 patients were in the microfracture group while 49 patients were in the microfracture/BMAC group. The minimum follow-up for both groups was 36 months. Both groups had a statistically significant improvement in pain scores, quality of life scores, participation in sport and activities of daily living. The revision rate was 28.8% in the microfracture group versus 12.2% in the microfracture/BMAC group, which was statistically significant, p=0.0145. The majority of the lesions were less than 1.5cm2 in diameter in both cohorts. CONCLUSIONS: Microfracture and bone marrow aspirate concentrate appears to be a safe and effective treatment option for osteochondral lesions of the talus. The addition of bone marrow aspirate concentrate does not result in any increase in ankle or donor site morbidity. It is a well-tolerated therapy which decreases revision rates for treatment of the osteochondral lesions when compared to microfracture alone. LEVEL OF EVIDENCE: Level III.
BACKGROUND: The term osteochondral lesion (OCL) refers to a defect involving the chondral surface and or subchondral bone. These lesions are associated with ankle injuries with bony and soft tissue and cause pain, decreased range of motion, swelling and impact adversely on quality of life. To date the standard treatment has been isolated microfracture (BMS). The aim of this study was to compare the outcomes of BMS alone to BMS augmented with bone marrow aspirate concentrate (BMAC) in the treatment of ankle OCLs. METHODS: This study was a prospective cohort study carried out from 2010-2015 in a single surgeon's practice. Patients from 2010-2012 were treated with microfracture alone while patients from 2013-2015 were treated with micro fracture augmented with bone marrow aspirate concentrate and fibrin glue. Self-reported patient outcome measures were measured. Complications, revision rates, and visual analogue pain scores were compared. RESULTS: 101 patients were included in the study. 52 patients were in the microfracture group while 49 patients were in the microfracture/BMAC group. The minimum follow-up for both groups was 36 months. Both groups had a statistically significant improvement in pain scores, quality of life scores, participation in sport and activities of daily living. The revision rate was 28.8% in the microfracture group versus 12.2% in the microfracture/BMAC group, which was statistically significant, p=0.0145. The majority of the lesions were less than 1.5cm2 in diameter in both cohorts. CONCLUSIONS: Microfracture and bone marrow aspirate concentrate appears to be a safe and effective treatment option for osteochondral lesions of the talus. The addition of bone marrow aspirate concentrate does not result in any increase in ankle or donor site morbidity. It is a well-tolerated therapy which decreases revision rates for treatment of the osteochondral lesions when compared to microfracture alone. LEVEL OF EVIDENCE: Level III.
Authors: Tim Dwyer; Graeme Hoit; Adrienne Lee; Elyse Watkins; Patrick Henry; Tim Leroux; Christian Veillette; John Theodoropoulos; Darrell Ogilvie-Harris; Jaskarndip Chahal Journal: Arthrosc Sports Med Rehabil Date: 2021-08-14
Authors: Sameera Abas; Jan Herman Kuiper; Sally Roberts; Helen McCarthy; Mike Williams; Andrew Bing; Bernhard Tins; Nilesh Makwana Journal: Cells Date: 2022-02-11 Impact factor: 6.600